Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong 16.5 percent year-on-year rise, slightly exceeding the estimate of Rs 7,854 crore.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
MarketWatch
10h
Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr
.
Reddy's
Laboratories
Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
1h
Dr. Reddy’s Labs Releases Unaudited Financial Results
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has released its unaudited financial results for the ...
5h
Neutral Dr Reddys Laboratories; target of Rs 1390: Motilal Oswal
Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...
1d
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
6h
Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
ndtvprofit
10h
Dr Reddy's Aims To Consistently Deliver Double-Digit Sales Growth, Ebitda Margin Of 25%
Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...
cnbctv18
17h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
4h
Reduce Dr. Reddy's Laboratories; target of Rs 1335 Prabhudas Lilladher
Dr
.
Reddy’s
(DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...
ndtvprofit
13h
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Business Insider
16h
Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions
Dr
.
Reddy’s
Laboratories
Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information
Dr
.
Reddy’s
Laboratories
Ltd presented to its investors.
Dr
.
Reddy’s
...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
Cinacalcet
Feedback